Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by bluebird bio, Inc.

< Previous 1 2 3 Next >
FDA Advisory Committee Unanimously Endorses eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio stock trading halted today June 9th and tomorrow June 10th
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Announces Posting of Briefing Documents for Upcoming FDA Advisory Committee Meeting
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Reports First Quarter 2022 Financial Results and Highlights Operational Progress
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Initiates Restructuring to Reduce Operating Expenses and Advance Near-term Opportunities to Bring Potentially Curative Gene Therapies to Patients in the US
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird Provides Update on FDA Review Timelines for Betibeglogene Autotemcel (beti-cel) for Beta-Thalassemia and Elivaldogene Autotemcel (eli-cel) for Cerebral Adrenoleukodystrophy (CALD)
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio to Provide Update on Program Milestones and 2022 Financial Outlook at the 40th Annual J.P. Morgan Healthcare Conference
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio to Present at the 40th Annual J.P. Morgan Healthcare Conference
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Announces Partial Clinical Hold for Patients Under 18 in Sickle Cell Gene Therapy Clinical Program
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Announces FDA Priority Review of Biologics License Application for eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) in Patients Without a Matched Sibling Donor
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
New and Updated Data Demonstrating Sustained Treatment Response in Patients Treated in Largest Sickle Cell Gene Therapy Program To-Date Presented at ASH21 and Published in NEJM
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
New Data at ASH21, Published in NEJM Further Demonstrate beti-cel as a Potentially Curative One-Time Gene Therapy for β-thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable TI and Normal or Near-Normal Adult Hb Levels
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Announces FDA Priority Review of Biologics License Application for beti-cel Gene Therapy for Patients with β-thalassemia Who Require Regular Red Blood Cell Transfusions
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Reports Third Quarter Financial Results and Recent Operational Progress
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio and Federal Realty to Establish Biotech Footprint at Assembly Row
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Completes Planned Business Separation
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Sets Record Date and Distribution Date for Planned Business Separation
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Provides Update on Upcoming Planned Business Separation
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Submits Biologics License Application (BLA) to FDA for betibeglogene autotemcel (beti-cel) Gene Therapy for Patients With β-thalassemia Who Require Regular Red Blood Cell Transfusions
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Secures $75 Million in Private Placement Equity Financing
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Announces Key Management and Board Appointments and Upcoming Investor Events
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Reports Second Quarter Financial Results and Provides Operational Update
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Announces Q2 Earnings Call and Upcoming Investor Events
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Receives EC Approval for SKYSONA™ (elivaldogene autotemcel, Lenti-D™) Gene Therapy for Patients Less Than 18 Years of Age With Early Cerebral Adrenoleukodystrophy (CALD) Without Matched Sibling Donor
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Announces Positive Recommendation by PRAC Regarding Article 20 Safety Referral Review of ZYNTEGLO™ Gene Therapy for Transfusion-Dependent β-thalassemia and Marketing to Resume in EU
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
betibeglogene autotemcel (beti-cel) One-Time Gene Therapy for β-thalassemia Continues to Demonstrate Durable Efficacy Across Pediatric and Adult Patient Populations and All Genotypes in Data Presented at EHA2021 Virtual
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio to Present at Goldman Sachs Global Healthcare Conference
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio, Inc. Reports Inducement Grants to CCO Tom Klima Under Nasdaq Listing Rule 5635(c)(4)
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Receives Positive CHMP Opinion for SKYSONA™ (elivaldogene autotemcel, Lenti-D™) Gene Therapy for Patients Less Than 18 Years of Age with Early Cerebral Adrenoleukodystrophy (CALD)
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS